Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Nov 24:12:1019911.
doi: 10.3389/fonc.2022.1019911. eCollection 2022.

Clinical features and therapeutic outcomes of alveolar soft part sarcoma in children: A single-center, retrospective study

Zhichao Tan  1 , Jiayong Liu  1 , Ruifeng Xue  1 , Zhengfu Fan  1 , Chujie Bai  1 , Shu Li  1 , Tian Gao  1 , Lu Zhang  1 , Xinyu Wang  1
Affiliations

Clinical features and therapeutic outcomes of alveolar soft part sarcoma in children: A single-center, retrospective study

Zhichao Tan et al. Front Oncol. .

Abstract

Background: Alveolar soft part sarcoma (ASPS) is a rare sarcoma that has been shown to be highly effective to antiangiogenic agents and immune checkpoint inhibitors, but most reported studies about ASPS were concentrated on adult population. In this study, we aimed to describe the clinical features and therapeutic outcomes of ASPS in children.

Methods: We retrospectively reviewed the records of patients with ASPS in our institution since Jan 2015. All patients included in this study were pathologically confirmed ASPS and aged under 12 years at the time of initial diagnosis. Demographic characteristics, tumor sizes, primary tumor sites, metastasis, treatments used, therapeutic responses and survivals were evaluated.

Results: We identified a total of 56 patients to be initially diagnosed as ASPS since Jan 2015. A predisposition of high occurrence in head and neck (32.1%) was observed (versus 41.1% in limbs and 21.4% in trunk). 26 (46.4%) patients developed metastasis at the time of diagnosis or during follow-up. Tumors in tongue, pharynx and larynx had the least likelihood to metastasize (7.7%, P<0.05). Observation was recommended for 15 stage IV patients with only pulmonary metastasis. 7 (46.7%) patients remained stable until last follow up. The 1-year PFS rate was 83.3% and median progression-free survival time (PFS) was 29.4 months. 15 patients with progressive disease received mono or combined therapy. 11 patients received PD-1 monotherapy. 2 patients achieved partial response and 5 stable disease. The overall response rate was 18.2%. The median PFS of this group was 22.0 months, and the 1-year PFS rate was 70.0%. 4 patients received a combination therapy of PD-1 inhibitors plus tyrosine kinase inhibitors. All of them remained stable. No disease-related death occurred during follow-up.

Conclusions: ASPS exhibits a higher occurrence in head and neck in children. ASPS originating from glossopharyngeal region tends to have a lower metastasis rate. ASPS displays a more indolent growth pattern in children, which makes observation a preferable choice for children with sole pulmonary metastasis. Pediatric ASPS appears to be less effective to targeted therapy and immunotherapy than adults. The treatment of progressive ASPS in children remains challenging.

Keywords: alveolar soft part sarcoma; clinical features; immunotherapy; pediatric; targeted therapy.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The reviewer LX declared a shared parent affiliation with the authors to the handling editor at the time of review.

Figures

Figure 1
Figure 1
Tumor metastasis from different origin. APRC, abdominal, pelvic and retroperitoneal cavity; TPL, tongue, pharynx and larynx.
Figure 2
Figure 2
(A) Event-free survival of localized ASPS; (B) Progression-free survival for the observation group; (C) Progression-free survival for the PD-1 monotherapy group.
See this image and copyright information in PMC

References

    1. Folpe AL, Deyrup AT. Alveolar soft-part sarcoma: a review and update. J Clin Pathol (2006) 59(11):1127–32. doi: 10.1136/jcp.2005.031120 - DOI - PMC - PubMed
    1. Lieberman PH, Brennan MF, Kimmel M, Erlandson RA, Garin-Chesa P, Flehinger BY. Alveolar soft-part sarcoma. a clinico-pathologic study of half a century. Cancer (1989) 63(1):1–13. doi: 10.1002/1097-0142(19890101)63:1<1::AID-CNCR2820630102>3.0.CO;2-E - DOI - PubMed
    1. Hodge JC, Pearce KE, Wang X, Wiktor AE, Oliveira AM, Greipp PT. Molecular cytogenetic analysis for TFE3 rearrangement in Xp11.2 renal cell carcinoma and alveolar soft part sarcoma: validation and clinical experience with 75 cases. Mod Pathol (2014) 27(1):113–27. - PubMed
    1. Ferrari A, Casanova M, Collini P, Meazza C, Luksch R, Massimino M, et al. Adult-type soft tissue sarcomas in pediatric-age patients: experience at the istituto nazionale tumori in Milan. J Clin Oncol (2005) 23(18):4021–30. doi: 10.1200/JCO.2005.02.053 - DOI - PubMed
    1. Hagerty BL, Aversa J, Diggs LP, Dominguez DA, Ayabe RI, Blakely AM, et al. Characterization of alveolar soft part sarcoma using a large national database. Surgery (2020) 168(5):825–30. doi: 10.1016/j.surg.2020.06.007 - DOI - PMC - PubMed

LinkOut - more resources